Bavarian Nordic has secured a DKK 200 million+ vaccine contract in Europe, bringing total public‑preparedness deals to over ...

Neuschwanstein Castle and three other royal residences built by King Ludwig II of Bavaria have been designated as UNESCO ...

Despite Africa bearing the brunt of infections and deaths, wealthy nations continue stockpiling Jynneos vaccine ...

Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 millio ...

Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from ...

Shares in Bavarian Nordic jumped Friday after the Danish vaccine maker reported forecast-beating first-quarter revenue and maintained full-year guidance. In morning Copenhagen trade, shares were ...

Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Free Report)’s share price hit a new 52-week low on Monday . The stock traded as low as $6.60 and last traded at $6.84, with a volume of 10147 shares.

Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Free Report) will likely be posting its quarterly earnings results on Wednesday, March 5th. Analysts expect Bavarian Nordic A/S to post earnings of $0.40 ...

About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines.

COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase ...

Bavarian Nordic A/S agreed to a deal with the world’s largest vaccine manufacturer, the Serum Institute of India Pvt, to make the Danish biotech firm’s mpox shot.

Bavarian Nordic A/S posted the largest decline among large stocks during the session, tumbling 17.4%, followed by Gubra A/S shares, which tumbled 11.1%.